194 related articles for article (PubMed ID: 19550145)
1. A microarray-based DNA methylation study of glioblastoma multiforme.
Martinez R; Martin-Subero JI; Rohde V; Kirsch M; Alaminos M; Fernandez AF; Ropero S; Schackert G; Esteller M
Epigenetics; 2009 May; 4(4):255-64. PubMed ID: 19550145
[TBL] [Abstract][Full Text] [Related]
2. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide methylation analyses in glioblastoma multiforme.
Lai RK; Chen Y; Guan X; Nousome D; Sharma C; Canoll P; Bruce J; Sloan AE; Cortes E; Vonsattel JP; Su T; Delgado-Cruzata L; Gurvich I; Santella RM; Ostrom Q; Lee A; Gregersen P; Barnholtz-Sloan J
PLoS One; 2014; 9(2):e89376. PubMed ID: 24586730
[TBL] [Abstract][Full Text] [Related]
4. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
5. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme.
Martinez R; Setien F; Voelter C; Casado S; Quesada MP; Schackert G; Esteller M
Carcinogenesis; 2007 Jun; 28(6):1264-8. PubMed ID: 17272309
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
7. DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma.
Bennett LB; Schnabel JL; Kelchen JM; Taylor KH; Guo J; Arthur GL; Papageorgio CN; Shi H; Caldwell CW
Genes Chromosomes Cancer; 2009 Sep; 48(9):828-41. PubMed ID: 19530241
[TBL] [Abstract][Full Text] [Related]
8. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome.
Bai Y; Zhang QG; Wang XH
Eur J Med Res; 2014 Dec; 19(1):66. PubMed ID: 25498217
[TBL] [Abstract][Full Text] [Related]
10. The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIMP3 in glioblastoma multiforme clinical outcomes.
Saraiva-Esperón U; Ruibal A; Herranz M
J Neurol Sci; 2014 Dec; 347(1-2):325-31. PubMed ID: 25467143
[TBL] [Abstract][Full Text] [Related]
11. A DNA hypermethylation module for the stem/progenitor cell signature of cancer.
Easwaran H; Johnstone SE; Van Neste L; Ohm J; Mosbruger T; Wang Q; Aryee MJ; Joyce P; Ahuja N; Weisenberger D; Collisson E; Zhu J; Yegnasubramanian S; Matsui W; Baylin SB
Genome Res; 2012 May; 22(5):837-49. PubMed ID: 22391556
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme.
Martinez R; Schackert G; Esteller M
J Neurooncol; 2007 Apr; 82(2):133-9. PubMed ID: 17048097
[TBL] [Abstract][Full Text] [Related]
13. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation profiles of long- and short-term glioblastoma survivors.
Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F
Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms.
Martin-Subero JI; Ammerpohl O; Bibikova M; Wickham-Garcia E; Agirre X; Alvarez S; Brüggemann M; Bug S; Calasanz MJ; Deckert M; Dreyling M; Du MQ; Dürig J; Dyer MJ; Fan JB; Gesk S; Hansmann ML; Harder L; Hartmann S; Klapper W; Küppers R; Montesinos-Rongen M; Nagel I; Pott C; Richter J; Román-Gómez J; Seifert M; Stein H; Suela J; Trümper L; Vater I; Prosper F; Haferlach C; Cruz Cigudosa J; Siebert R
PLoS One; 2009 Sep; 4(9):e6986. PubMed ID: 19750229
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of testis derived transcript gene promoter significantly correlates with worse outcomes in glioblastoma patients.
Wang LJ; Bai Y; Bao ZS; Chen Y; Yan ZH; Zhang W; Zhang QG
Chin Med J (Engl); 2013; 126(11):2062-6. PubMed ID: 23769558
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
20. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
